Skip to main content

Table 4 Results of multivariable logistic regression predicting likelihood of ≥ 50% response in MHD

From: Impact of a reimbursement policy change on treatment with erenumab in migraine – a real-world experience from Germany

 

Coefficient (β)

S.E

Wald

df

P

Odds Ratio

95% CI for Odds Ratio

Lower

Upper

New policy

0.89

0.40

4.86

1

0.03

2.44

1.10

5.39

Sex (female)

-0.51

0.41

1.58

1

0.21

0.60

0.27

1.33

Age (yrs)

-0.01

0.02

0.16

1

0.69

0.99

0.96

1.03

Disease duration (yrs)

0.01

0.02

0.26

1

0.61

1.01

0.98

1.04

MHD at baseline

-0.44

0.04

1.52

1

0.22

0.96

0.89

1.03

Daily headaches

0.06

0.67

0.01

1

0.93

1.06

0.29

3.91

Start with 140 mg

0.08

0.44

0.04

1

0.85

1.09

0.46

2.57

Comorbid depression

-0.53

0.33

2.65

1

0.10

0.59

0.31

1.12

Chronic migraine

-0.13

0.35

0.14

1

0.71

0.88

0.45

1.73

Constant

0.93

0.90

1.07

1

0.30

2.54

  
  1. Variables included in the model: old vs. new policy, sex, age, disease duration, MHD (monthly headache days) at baseline, the presence of daily headaches, erenumab starting dose of 140 mg, comorbid depression, and chronic migraine
  2. Abbreviations: MHD monthly headache days S.E. standard error CI confidence interval